Latest Pharma Insights
Atrogi Bets On Muscle Preservation And Exercise Mimetics To Drive Obesity Push
Atrogi is betting that preserving muscle will define the next wave of obesity treatments, with its drug ATR-258 aiming to deliver exercise-like metabolic benefits.
Scrip - April 3, 2026
Atrogi is betting that preserving muscle will define the next wave of obesity treatments, with its drug ATR-258 aiming to deliver exercise-like metabolic benefits.
Scrip - April 3, 2026
Lipocine’s Oral Formulation Of Zulresso Fails Postpartum Depression Trial
The Phase III miss leaves Lipocine weighing its next steps as the field narrows to a single approved therapy for postpartum depression and limited options in development.
Scrip - April 3, 2026
The Phase III miss leaves Lipocine weighing its next steps as the field narrows to a single approved therapy for postpartum depression and limited options in development.
Scrip - April 3, 2026
US Shields Generics From Tariffs Amid Supply Chain Concerns
New US tariffs of up to 100% on patented drugs have spared generics and biosimilars for now, highlighting their role in supply chains, but officials have ordered a review of the sector within one year.
Generics Bulletin - April 3, 2026
New US tariffs of up to 100% on patented drugs have spared generics and biosimilars for now, highlighting their role in supply chains, but officials have ordered a review of the sector within one year.
Generics Bulletin - April 3, 2026
‘It’s Day And Night’ – Haruvi On How The AAM Has Evolved
In the second part of Generics Bulletin’s interview with Keren Haruvi, the Sandoz executive talks about her role as outgoing chair of the US Association for Accessible Medicines, and the achievements made by the group since it came under new leadership.
Generics Bulletin - April 3, 2026
In the second part of Generics Bulletin’s interview with Keren Haruvi, the Sandoz executive talks about her role as outgoing chair of the US Association for Accessible Medicines, and the achievements made by the group since it came under new leadership.
Generics Bulletin - April 3, 2026
Hyloris Warns Valacyclovir Launch Could Slip Into 2027
Hyloris has received a CRL from the US FDA for its valacyclovir oral liquid due to manufacturing issues at its CDMO, with no concerns on the product itself, and warns resolution could delay approval into 2027 as it explores alternative production options.
Generics Bulletin - April 3, 2026
Hyloris has received a CRL from the US FDA for its valacyclovir oral liquid due to manufacturing issues at its CDMO, with no concerns on the product itself, and warns resolution could delay approval into 2027 as it explores alternative production options.
Generics Bulletin - April 3, 2026
GDUFA IV: US FDA Worries About Revenue Shortfalls, Industry Does Not
The FDA said chronic under-collection of GDUFA revenue could create budget problems going forward unless the system is changed, but industry does not want to endanger the generic sector with higher fees.
Generics Bulletin - April 3, 2026
The FDA said chronic under-collection of GDUFA revenue could create budget problems going forward unless the system is changed, but industry does not want to endanger the generic sector with higher fees.
Generics Bulletin - April 3, 2026
Executives On The Move: Five CEOs And Six CFOs Among This Week’s Changes
Recent moves in the industry include C-suite changes at Aurinia Pharmaceuticals, Averna Therapeutics and Biocon, plus new director appointments at Novo Nordisk and Takeda.
Scrip - April 3, 2026
Recent moves in the industry include C-suite changes at Aurinia Pharmaceuticals, Averna Therapeutics and Biocon, plus new director appointments at Novo Nordisk and Takeda.
Scrip - April 3, 2026
Glenmark Reshapes US Ryaltris Strategy, Steps Away From Hikma Tie-Up
Glenmark is going solo with direct commercialization and distribution plans for Ryaltris in the US, effectively parting ways with partner Hikma.
Scrip - April 3, 2026
Glenmark is going solo with direct commercialization and distribution plans for Ryaltris in the US, effectively parting ways with partner Hikma.
Scrip - April 3, 2026
Bayer’s Men’s Pre-Conception Health Multivitamin Ad Claims Fail To Launch In NAD Review
NAD recommends Bayer HealthCare pull express claims including “Men’s Pre-Conception Health Complete Multivitamin to Support Healthy Sperm designed to provide nutritional support while trying to conceive.”
HBW Insight - April 3, 2026
NAD recommends Bayer HealthCare pull express claims including “Men’s Pre-Conception Health Complete Multivitamin to Support Healthy Sperm designed to provide nutritional support while trying to conceive.”
HBW Insight - April 3, 2026
LG Builds Global Oncology Ambitions With Novel Frontier Asset
Deal for first-in-class covalent p53 Y220C activator from Frontier's platform pushes Korean firm further along road to becoming global oncology player.
Scrip - April 3, 2026
Deal for first-in-class covalent p53 Y220C activator from Frontier's platform pushes Korean firm further along road to becoming global oncology player.
Scrip - April 3, 2026
Atrogi Bets On Muscle Preservation And Exercise Mimetics To Drive Obesity Push
Atrogi is betting that preserving muscle will define the next wave of obesity treatments, with its drug ATR-258 aiming to deliver exercise-like metabolic benefits.
Scrip - April 3, 2026
Atrogi is betting that preserving muscle will define the next wave of obesity treatments, with its drug ATR-258 aiming to deliver exercise-like metabolic benefits.
Scrip - April 3, 2026
Lipocine’s Oral Formulation Of Zulresso Fails Postpartum Depression Trial
The Phase III miss leaves Lipocine weighing its next steps as the field narrows to a single approved therapy for postpartum depression and limited options in development.
Scrip - April 3, 2026
The Phase III miss leaves Lipocine weighing its next steps as the field narrows to a single approved therapy for postpartum depression and limited options in development.
Scrip - April 3, 2026
Executives On The Move: Five CEOs And Six CFOs Among This Week’s Changes
Recent moves in the industry include C-suite changes at Aurinia Pharmaceuticals, Averna Therapeutics and Biocon, plus new director appointments at Novo Nordisk and Takeda.
Scrip - April 3, 2026
Recent moves in the industry include C-suite changes at Aurinia Pharmaceuticals, Averna Therapeutics and Biocon, plus new director appointments at Novo Nordisk and Takeda.
Scrip - April 3, 2026
Glenmark Reshapes US Ryaltris Strategy, Steps Away From Hikma Tie-Up
Glenmark is going solo with direct commercialization and distribution plans for Ryaltris in the US, effectively parting ways with partner Hikma.
Scrip - April 3, 2026
Glenmark is going solo with direct commercialization and distribution plans for Ryaltris in the US, effectively parting ways with partner Hikma.
Scrip - April 3, 2026
LG Builds Global Oncology Ambitions With Novel Frontier Asset
Deal for first-in-class covalent p53 Y220C activator from Frontier's platform pushes Korean firm further along road to becoming global oncology player.
Scrip - April 3, 2026
Deal for first-in-class covalent p53 Y220C activator from Frontier's platform pushes Korean firm further along road to becoming global oncology player.
Scrip - April 3, 2026
Execs On The Move: March 23–27, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - April 2, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - April 2, 2026
Whoop Raises $575M At $10.1Bn Valuation With Abbott on Board As Oura And Google Close In
The company, which ships to 56 countries and operates in six languages, said it ended last year booking deals at an annual pace of about $1.1 billion– up 103% year over year – and said it is hiring for more than 600 new roles globally in 2026.
Medtech Insight - April 2, 2026
The company, which ships to 56 countries and operates in six languages, said it ended last year booking deals at an annual pace of about $1.1 billion– up 103% year over year – and said it is hiring for more than 600 new roles globally in 2026.
Medtech Insight - April 2, 2026
Force Majeure, 35% Spike In Plastics Costs: Middle East Conflict Hits Medical Supply Chains
Five weeks into the Middle Eastern war, petrochemical force majeure declarations are being filed, prices for a key petrochemical used in plastics are up 35% and the supply chains that produce IV bags, syringes and catheters are under compounding pressure.
Medtech Insight - April 2, 2026
Five weeks into the Middle Eastern war, petrochemical force majeure declarations are being filed, prices for a key petrochemical used in plastics are up 35% and the supply chains that produce IV bags, syringes and catheters are under compounding pressure.
Medtech Insight - April 2, 2026
China Issues Global-First Approval For SPECT/CT Imaging Agent For Tumor Diagnosis
The technetium-99m labeled, integrin ?V?3-targeting 99mTc-3PRGD2 has been approved in China as the world’s first SPECT/CT imaging agent for the diagnosis of tumors.
Medtech Insight - April 2, 2026
The technetium-99m labeled, integrin ?V?3-targeting 99mTc-3PRGD2 has been approved in China as the world’s first SPECT/CT imaging agent for the diagnosis of tumors.
Medtech Insight - April 2, 2026
Bayer’s Men’s Pre-Conception Health Multivitamin Ad Claims Fail To Launch In NAD Review
NAD recommends Bayer HealthCare pull express claims including “Men’s Pre-Conception Health Complete Multivitamin to Support Healthy Sperm designed to provide nutritional support while trying to conceive.”
HBW Insight - April 3, 2026
NAD recommends Bayer HealthCare pull express claims including “Men’s Pre-Conception Health Complete Multivitamin to Support Healthy Sperm designed to provide nutritional support while trying to conceive.”
HBW Insight - April 3, 2026
US Shields Generics From Tariffs Amid Supply Chain Concerns
New US tariffs of up to 100% on patented drugs have spared generics and biosimilars for now, highlighting their role in supply chains, but officials have ordered a review of the sector within one year.
Generics Bulletin - April 3, 2026
New US tariffs of up to 100% on patented drugs have spared generics and biosimilars for now, highlighting their role in supply chains, but officials have ordered a review of the sector within one year.
Generics Bulletin - April 3, 2026
‘It’s Day And Night’ – Haruvi On How The AAM Has Evolved
In the second part of Generics Bulletin’s interview with Keren Haruvi, the Sandoz executive talks about her role as outgoing chair of the US Association for Accessible Medicines, and the achievements made by the group since it came under new leadership.
Generics Bulletin - April 3, 2026
In the second part of Generics Bulletin’s interview with Keren Haruvi, the Sandoz executive talks about her role as outgoing chair of the US Association for Accessible Medicines, and the achievements made by the group since it came under new leadership.
Generics Bulletin - April 3, 2026
Hyloris Warns Valacyclovir Launch Could Slip Into 2027
Hyloris has received a CRL from the US FDA for its valacyclovir oral liquid due to manufacturing issues at its CDMO, with no concerns on the product itself, and warns resolution could delay approval into 2027 as it explores alternative production options.
Generics Bulletin - April 3, 2026
Hyloris has received a CRL from the US FDA for its valacyclovir oral liquid due to manufacturing issues at its CDMO, with no concerns on the product itself, and warns resolution could delay approval into 2027 as it explores alternative production options.
Generics Bulletin - April 3, 2026
GDUFA IV: US FDA Worries About Revenue Shortfalls, Industry Does Not
The FDA said chronic under-collection of GDUFA revenue could create budget problems going forward unless the system is changed, but industry does not want to endanger the generic sector with higher fees.
Generics Bulletin - April 3, 2026
The FDA said chronic under-collection of GDUFA revenue could create budget problems going forward unless the system is changed, but industry does not want to endanger the generic sector with higher fees.
Generics Bulletin - April 3, 2026
Europe’s Biotech Edge Lies In Science-First Investing
Despite tough markets and geopolitical uncertainty, Matthieu Coutet sees strong deal flow, rising investor appetite and big opportunities in fibrosis, with Sofinnova Partners taking an active role in building companies through series A and beyond.
In Vivo - April 2, 2026
Despite tough markets and geopolitical uncertainty, Matthieu Coutet sees strong deal flow, rising investor appetite and big opportunities in fibrosis, with Sofinnova Partners taking an active role in building companies through series A and beyond.
In Vivo - April 2, 2026